Hepatitis C Articles (HCV)
Back
	Abbott HCV Boosted Protease ABT450 Blocks Protease Mutations/155 Similar as in HIV       EASL/2011: Genotypic and Phenotypic Characterization of NS3 Variants Selected in HCV-Infected Patients Treated with ABT-450 - (04/05/11)   EASL/2012: A 12-Week Interferon-Free Regimen of ABT-450/r, ABT-072, and Ribavirin was Well Tolerated and Achieved Sustained Virologic Response in 91% Treatment-Naïve HCV IL28B-CC Genotype-1-Infected Subjects - (04/19/12)   EASL/2012: A 12-Week Interferon-Free Regimen of ABT-450/r + ABT-333 + Ribavirin Achieved SVR12 in More Than 90% of Treatment-Naïve HCV Genotype-1-Infected Subjects and 47% of Previous Non-Responders - (04/23/12)   EASL 47th Annual Meeting Barcelona, Spain April 18th - 22nd 2012           View Older Articles   Back to Top   www.natap.org